Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.77 |
| ▸ | ATRIP | Q8WXE1 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140478 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17527632 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501168 | 0.81 | ATR (1.00) | ATRATRIP | |
| SCHEMBL20081803 | 0.79 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501120 | 0.79 | ATR (1.00) | ATRATRIP | |
| SCHEMBL20081936 | 0.79 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501287 | 0.79 | ATR (1.00) | ATRATRIP | |
| SCHEMBL30140464 | 0.78 | ATR (1.00) | ATRATRIP | |
| SCHEMBL18110049 | 0.78 | ATR (1.00) | ATRATRIP | |
| SCHEMBL30140531 | 0.78 | ATR (1.00) | ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | ATR, PDCD1, CHEK1 | ATR 1/4885ATRIP 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.